MA54525A - Anticorps bispécifiques clec12axcd3 et méthodes de traitement d'une maladie - Google Patents

Anticorps bispécifiques clec12axcd3 et méthodes de traitement d'une maladie

Info

Publication number
MA54525A
MA54525A MA054525A MA54525A MA54525A MA 54525 A MA54525 A MA 54525A MA 054525 A MA054525 A MA 054525A MA 54525 A MA54525 A MA 54525A MA 54525 A MA54525 A MA 54525A
Authority
MA
Morocco
Prior art keywords
disease
treating
methods
bispecific antibodies
bispecific
Prior art date
Application number
MA054525A
Other languages
English (en)
Inventor
Alexander Berthold Hendrik Bakker
Cornelis Jacob Johannes George Bol
Leonardo Andres Sirulnik
Loo Pieter Fokko Van
Ernesto Isaac Wasserman
Original Assignee
Merus Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merus Nv filed Critical Merus Nv
Publication of MA54525A publication Critical patent/MA54525A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
MA054525A 2018-12-20 2019-12-20 Anticorps bispécifiques clec12axcd3 et méthodes de traitement d'une maladie MA54525A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18214478 2018-12-20

Publications (1)

Publication Number Publication Date
MA54525A true MA54525A (fr) 2021-10-27

Family

ID=65013454

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054525A MA54525A (fr) 2018-12-20 2019-12-20 Anticorps bispécifiques clec12axcd3 et méthodes de traitement d'une maladie

Country Status (7)

Country Link
US (2) US11873338B2 (fr)
EP (1) EP3898685A1 (fr)
JP (2) JP2022521036A (fr)
CN (2) CN113366018A (fr)
MA (1) MA54525A (fr)
TW (2) TW202604961A (fr)
WO (1) WO2020130829A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015037311A1 (fr) * 2013-09-10 2015-03-19 日立化成株式会社 Suspension, ensemble de liquide de polissage, liquide de polissage, procédé de polissage d'un substrat, et substrat
CN113366018A (zh) 2018-12-20 2021-09-07 美勒斯公司 用于治疗疾病的CLEC12AxCD3双特异性抗体和方法
EP4373856A4 (fr) * 2021-07-20 2025-06-18 ABL Bio Inc. Anticorps anti-cll-1 et leurs utilisations
CA3252868A1 (fr) * 2022-02-28 2023-08-31 Jasper Therapeutics, Inc. Compositions et procédés pour la déplétion de cellules souches hématopoïétiques malades
WO2024036139A2 (fr) * 2022-08-09 2024-02-15 Qlsf Biotherapeutics, Inc. Anticorps se liant à clec12a

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ543635A (en) 2003-06-25 2008-05-30 Crucell Holland Bv Human C-type lectin: a suitable target molecule for binding molecules, particularly immunoconjugates, in the diagnosis, prevention and/or treatment of myeloid neoplastic diseases such as AML and CML
SG188175A1 (en) 2004-06-03 2013-03-28 Novimmune Sa Anti-cd3 antibodies and methods of use thereof
EP2471816A1 (fr) 2006-08-30 2012-07-04 Genentech, Inc. Anticorps multi-spécifiques
EP3456191A1 (fr) 2008-06-27 2019-03-20 Merus N.V. Mammifères non humains produisant un anticorps
KR20150036824A (ko) 2009-03-20 2015-04-07 제넨테크, 인크. 이중특이적 항-ｈｅｒ 항체
JP6251570B2 (ja) 2010-09-21 2017-12-20 アルター・バイオサイエンス・コーポレーション 多量体ｉｌ−１５可溶性融合分子並びにその製造及び使用方法
WO2013157953A1 (fr) 2012-04-20 2013-10-24 Merus B.V. Procédés et moyens de production de molécules de type ig
BR112015006824A2 (pt) 2012-09-27 2017-07-04 Merus B V anticorpo igg biespecífico, método para produzir um anticorpo igg biespecífico, anticorpo, composição farmacêutica e uso de um anticorpo igg biespecífico
EP3028538B1 (fr) 2013-08-02 2024-05-22 BSH Hausgeräte GmbH Système de table de cuisson
TW201718647A (zh) * 2015-06-16 2017-06-01 建南德克公司 抗-cll-1抗體及使用方法
WO2017010874A1 (fr) * 2015-07-10 2017-01-19 Merus N.V. Anticorps se liant à un cd3 humain
WO2017167350A1 (fr) * 2016-03-30 2017-10-05 Horst Lindhofer Anticorps multispécifiques destinés à être utilisés pour le traitement d'un néoplasme du tractus urinaire
JOP20170091B1 (ar) 2016-04-19 2021-08-17 Amgen Res Munich Gmbh إعطاء تركيبة ثنائية النوعية ترتبط بـ cd33 وcd3 للاستخدام في طريقة لعلاج اللوكيميا النخاعية
EP3541843A1 (fr) * 2016-11-15 2019-09-25 Genentech, Inc. Dosage pour le traitement avec des anticorps bispécifiques anti-cd20/anti-cd3
CN113366018A (zh) 2018-12-20 2021-09-07 美勒斯公司 用于治疗疾病的CLEC12AxCD3双特异性抗体和方法

Also Published As

Publication number Publication date
JP2022521036A (ja) 2022-04-05
TWI908715B (zh) 2025-12-21
CN113366018A (zh) 2021-09-07
WO2020130829A1 (fr) 2020-06-25
US20220010013A1 (en) 2022-01-13
US12503509B2 (en) 2025-12-23
CN114344461A (zh) 2022-04-15
TW202034952A (zh) 2020-10-01
US11873338B2 (en) 2024-01-16
JP2024144441A (ja) 2024-10-11
EP3898685A1 (fr) 2021-10-27
US20240262912A1 (en) 2024-08-08
TW202604961A (zh) 2026-02-01

Similar Documents

Publication Publication Date Title
MA51631A (fr) Anticorps anti-pd1 et méthodes de traitement
MA51677A (fr) Méthodes de traitement du cancer à l'aide d'anticorps anti-pd-1
MA71708A (fr) Méthodes de traitement du cancer avec des anticorps bispécifiques anti-cd3xmuc16 et des anticorps anti-pd-1
EP3920923A4 (fr) Agents thérapeutiques et méthodes de traitement
MA54132A (fr) Méthodes de traitement de la maladie de crohn avec un anticorps spécifique anti-il23
FR25C1007I1 (fr) Formulations d'épinéphrine intranasale et méthodes de traitement d'une maladie
EP3402533A4 (fr) Méthodes et compositions pour le traitement d'une maladie neurologique
MA52631A (fr) Compositions et méthodes pour le traitement de la maladie de parkinson
EP3762505A4 (fr) Compositions et méthodes pour le traitement de la maladie de parkinson
EP3846830A4 (fr) Méthodes et compositions pour le traitement de maladie musculo-squelettiques
EP3790540A4 (fr) Méthodes de traitement et de limitation du developpement de troubles neurologiques liés à une maladie cardiovasculaire
EP3790867A4 (fr) Inhibiteurs de kdm1a pour le traitement d'une maladie
MA45997A (fr) Méthodes de traitement de la maladie de crohn avec un anticorps anti-nkg2d
MA54313A (fr) Méthodes de traitement d'une maladie à l'aide d'inhibiteurs de magl
EP3773632A4 (fr) Méthodes de traitement de glioblastomes exprimant l'egfrviii
MA48751A (fr) Paradigme de traitement pour un traitement combiné d'anticorps anti-cd19 et de venetoclax
MA46842A (fr) Méthodes de traitement de l'obésité au moyen d'anticorps anti-angptl8
MA54229A (fr) Composés et compositions destinés au traitement d'états pathologiques associés à une activité de nlrp
MA55375A (fr) Méthodes thérapeutiques de traitement de l'hépatite b
EP3716949A4 (fr) Méthodes de traitement d'une maladie auto-immune
MA51787A (fr) Substances et méthodes de traitement d'hémoglobinopathies
EP3920940A4 (fr) Méthodes de prévention et de traitement d'une inflammation et d'une maladie inflammatoire
EP3976053A4 (fr) Compositions et méthodes de traitement d'une maladie métabolique
EP3952859A4 (fr) Méthodes de traitement de la maladie de niemann-pick de type c
MA54827A (fr) Méthodes de traitement d'une maladie à l'aide d'inhibiteurs de magl